Supplementary Video 1 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Supplementary Video 1 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

<p>Supplementary Video 1</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Debarati Mukherjee (15134436) (author)
Andere auteurs:	Rebecca A. Previs (16918344) (author), Corinne Haines (16918347) (author), Muthana Al Abo (16918350) (author), Patrick K. Juras (15134430) (author), Kyle C. Strickland (16918353) (author), Binita Chakraborty (16918356) (author), Sandeep Artham (15086158) (author), Regina S. Whitaker (16918359) (author), Katherine Hebert (16918362) (author), Jake Fontenot (16918365) (author), Steven R. Patierno (16918368) (author), Jennifer A. Freedman (16918371) (author), Frank H. Lau (16918374) (author), Matthew E. Burow (16918377) (author), Ching-Yi Chang (15134445) (author), Donald P. McDonnell (15051446) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Tumor Biology Molecular and Cellular Biology Therapeutic Research and Development Breast Cancer Cell Signaling Protein serine-threonine kinases Drug Targets Protein kinase & phosphatase drug targets Progression, Invasion & Metastasis Metastasis Migration and invasion
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Supplementary Video 2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
door: Debarati Mukherjee (15134436)
Gepubliceerd in: (2025)

Supplementary Video 3 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
door: Debarati Mukherjee (15134436)
Gepubliceerd in: (2025)

Supplementary Video 4 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
door: Debarati Mukherjee (15134436)
Gepubliceerd in: (2025)

Supplementary Movie S1 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
door: Jesse C. Patterson (14962862)
Gepubliceerd in: (2025)

Supplementary Movie S2 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
door: Jesse C. Patterson (14962862)
Gepubliceerd in: (2025)

Supplementary Movie S3 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
door: Jesse C. Patterson (14962862)
Gepubliceerd in: (2025)

Supplementary Movie S4 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
door: Jesse C. Patterson (14962862)
Gepubliceerd in: (2025)

Supplementary Movie S5 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
door: Jesse C. Patterson (14962862)
Gepubliceerd in: (2025)

Supplementary Movie S6 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
door: Jesse C. Patterson (14962862)
Gepubliceerd in: (2025)

Supplementary Movie S7 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
door: Jesse C. Patterson (14962862)
Gepubliceerd in: (2025)

Supplementary Movie S8 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
door: Jesse C. Patterson (14962862)
Gepubliceerd in: (2025)

Supplementary Movie S9 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
door: Jesse C. Patterson (14962862)
Gepubliceerd in: (2025)

Supplementary Table S1 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
door: Clare F. Malone (14960925)
Gepubliceerd in: (2025)

Supplementary Table S2 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
door: Clare F. Malone (14960925)
Gepubliceerd in: (2025)

Supplementary Table S3 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
door: Clare F. Malone (14960925)
Gepubliceerd in: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
door: Katie E. Hebron (15046889)
Gepubliceerd in: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
door: Katie E. Hebron (15046889)
Gepubliceerd in: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
door: Katie E. Hebron (15046889)
Gepubliceerd in: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
door: Katie E. Hebron (15046889)
Gepubliceerd in: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
door: Katie E. Hebron (15046889)
Gepubliceerd in: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
door: Katie E. Hebron (15046889)
Gepubliceerd in: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
door: Katie E. Hebron (15046889)
Gepubliceerd in: (2025)

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
door: Evan C. Chen (15054014)
Gepubliceerd in: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
door: Evan C. Chen (15054014)
Gepubliceerd in: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
door: Evan C. Chen (15054014)
Gepubliceerd in: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
door: Evan C. Chen (15054014)
Gepubliceerd in: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
door: Evan C. Chen (15054014)
Gepubliceerd in: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
door: Evan C. Chen (15054014)
Gepubliceerd in: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
door: Srivandana Akshintala (16610490)
Gepubliceerd in: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
door: Srivandana Akshintala (16610490)
Gepubliceerd in: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
door: Erwin Tomasich (15052256)
Gepubliceerd in: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
door: Erwin Tomasich (15052256)
Gepubliceerd in: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
door: Erwin Tomasich (15052256)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_at2vaj26godrtovnc3cb7sa08m